Apixaban + Standard of care

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Symptomatic Aortic Stenosis

Conditions

Symptomatic Aortic Stenosis, Eligible for Transcatheter Aortic Valve Replacement

Trial Timeline

Aug 26, 2016 → Oct 15, 2020

NCT ID

NCT02664649

About Apixaban + Standard of care

Apixaban + Standard of care is a phase 3 stage product being developed by Pfizer for Symptomatic Aortic Stenosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02664649. Target conditions include Symptomatic Aortic Stenosis, Eligible for Transcatheter Aortic Valve Replacement.

What happened to similar drugs?

3 of 16 similar drugs in Symptomatic Aortic Stenosis were approved

Approved (3) Terminated (4) Active (9)

❌Sodium hyaluronate + placebo injectionDaiichi SankyoPhase 3

🔄ISV-305Sun PharmaceuticalPhase 3

🔄rabeprazole sodium + PlaceboEisaiPhase 3

🔄Esomeprazole + Matching placeboAstraZenecaPhase 3

🔄Pasireotide + OctreotideNovartisPhase 3

✅valsartanNovartisApproved

❌Azithromycin plus chloroquinePfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02664649	Phase 3	Completed	Aug 26, 2016	Oct 15, 2020	Symptomatic Aortic Stenosis
NCT02464969	Approved	Completed	Nov 22, 2015	Apr 30, 2024	Venous Thromboembolism

Competing Products

20 competing products in Symptomatic Aortic Stenosis

See all competitors

Product	Company	Stage	Hype Score
Sodium hyaluronate + placebo injection	Daiichi Sankyo	Phase 3	32
ISV-305	Sun Pharmaceutical	Phase 3	40
rabeprazole sodium + Placebo	Eisai	Phase 3	40
Verinurad + Febuxostat + Dapagliflozin	AstraZeneca	Phase 2	35
RDEA3170 + Febuxostat + Benzbromarone	AstraZeneca	Phase 1/2	32
Esomeprazole + Matching placebo	AstraZeneca	Phase 3	40
DFV890 + Placebo	Novartis	Phase 2	35
Omalizumab + Omalizumab + Placebo	Novartis	Phase 2	35
Pasireotide + Octreotide	Novartis	Phase 3	40
Tegaserod	Novartis	Phase 2	35
valsartan	Novartis	Approved	43
Atorvastatin - Cholestyramine - Sitosterol	Pfizer	Pre-clinical	26
Epoetin biosimilar	Pfizer	Pre-clinical	26
Azithromycin plus chloroquine	Pfizer	Phase 3	32
Mavacamten	Bristol Myers Squibb	Approved	50
Aficamten + Placebo	Sanofi	Phase 3	44
Vandetanib 300 mg	Sanofi	Pre-clinical	26
REGN7508 + Acetylsalicylic Acid (ASA) + Placebo	Regeneron Pharmaceuticals	Phase 3	47
Rivaroxaban + Placebo	Bayer	Phase 3	37
Droxidopa capsules + Placebo capsules	Lundbeck	Approved	40